H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine (IRON – Research Report) today and set a price target of $118.00.

HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $18.00 price ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the“Company”), a leader in blockchain infrastructure and technology, has announced its ...

HC Wainwright decreased their Q3 2025 EPS estimates for shares of Applied Digital in a research note issued to investors on ...

Fintel reports that on January 17, 2025, HC Wainwright & Co. downgraded their outlook for CECO Environmental (NasdaqGS:CECO) ...

Microbot Medical Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 51.85%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and $50.00 price target for Akero Therapeutics (NASDAQ:AKRO), representing significant upside potential from the current trading price of $24.01.

On Wednesday, H.C. Wainwright reaffirmed a Buy rating on shares of TG Therapeutics (NASDAQ:TGTX) shares with a steady price target of $55.00. The firm's analyst highlighted the company's strong ...

H.C. Wainwright has recently initiated Gryphon Digital Mining Inc (GRYP) stock to Neutral rating, as announced on July 30, 2024, according to Finviz. Earlier, on July 23, 2021, Lake Street had ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...